The multi-year patent dispute between Masimo and Apple resulted in major legal actions, including a U.S. International Trade Commission import ban that forced Apple to temporarily halt or modify blood oxygen tracking features on certain watch models. Furthermore, a federal jury ordered Apple to pay Masimo hundreds of millions of dollars in damages for infringing upon pulse-oximetry patent rights across tens of millions of devices sold, though legal appeals and secondary design workarounds continue to evolve.